Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

Issue Archive

Table of Contents

T cell exhaustion and an immunosuppressive microenvironment is a hallmark of CTCL. Durvalumab combined with lenalidomide has the potential to enhance anti-tumor immunity in CTCL.

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals